The UCSF Helen Diller Family Comprehensive Cancer Center was awarded the Specialized Programs of Research Excellence grant by NCI for a combined program focused on cancer outcomes.
The Liver Tumor Program at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center has been selected by NCI as a Specialized Program of Research Excellence.
Yale Cancer Center’s Specialized Program of Research Excellence in Lung Cancer was awarded a renewal grant from NCI for year 11 of the program.
The NCI Community Oncology Research Program selected Kathleen Yost Butler and Kamara Mertz-Rivera as recipients of this year’s outstanding principal investigator and administrator, respectively, at the 2025 NCORP annual meeting in Bethesda.
Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.
The National Cancer Advisory Board approved five reissue concepts at a meeting Sept. 4.
As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.
The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding.
